The equities research experts at StockNews.com raised their recommendation for Teleflex (NYSE: TFX), moving it from a “hold” rating to a “buy” rating in a report that was published on Wednesday.
TFX has been brought up in conversations by a few other research experts.
A research report published on Friday, February 24th, by Needham & Company LLC reiterated a “buy” rating on shares of Teleflex and set a target price of $291.00 for the company’s stock. Stephens increased their price target on Teleflex from $280.00 to $295.00 and rated the stock as “overweight” in a report released on Wednesday, December 28th.
Morgan Stanley increased their target price on Teleflex from $236.00 to $280.00 and gave the company an “equal weight” rating in a report published on Friday, January 6th.
Truist Financial lowered their price objective on Teleflex from $260.00 to $250.00 and rated the stock as a “hold” in a report released on Monday, February 27th. Raymond James increased their price target on Teleflex from $231.00 to $259.00 and gave the company an “outperform” rating in a research report published on Friday, February 24th. Six analysts believe investors should maintain their holdings in the company, while seven believe investors should purchase it.
According to Bloomberg, the current consensus rating for Teleflex is “Moderate Buy,” and the stock’s price objective is $271.69.
The price of TFX stock was $244.87 when the market opened on Wednesday.
The company’s moving average over the past 50 days is $240.19, and its moving average over the past 200 days is $229.60.
The 52-week low for Teleflex is $182.65, while the 52-week high for the stock is $356.72.
The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.43, and a current ratio of 2.43.
The company has a market capitalization of $11.49 billion, a price-to-earnings ratio of 31.88, a price-to-earnings-growth ratio of 2.47, and a beta of 0.98.
The most recent quarterly earnings report for Teleflex (NYSE: TFX) was released on February 23rd, a Thursday.
Earnings per share for the company specializing in medical technology came in at $3.52, $0.08 more than the consensus estimate of $3.44.
The return on equity for Teleflex was 15.87%, and the company’s net margin was 13.01%.
The revenue for the quarter came in at $760 million less than what analysts had predicted, which was $760.29 million.
During the same quarter the previous year, the company generated $3.60 per share earnings.
The company experienced a decrease of 0.5% year over year in revenue for the quarter.
According to the forecasts of market research analysts, Teleflex will generate earnings of 13.29 cents per share in 2018.
Several significant investors bought and sold business stock during the most recent period.
T. Rowe Price Investment Management INC increased the percentage of Teleflex stock it owns by 2.1% during the fourth quarter.
After purchasing an additional 181,393 shares during the period, T. Rowe Price Investment Management INC has 8,633,473 shares of the medical technology company’s stock, currently valued at $2,155,174,000.
Price T. Rowe Associates INC (MD) boosted its holdings in Teleflex by 20.3% during the second quarter of the fiscal year.
Price T. Rowe Associates INC (MD) now owns 8,335,146 shares of the medical technology business after making an additional purchase of 1,407,946 shares during that time.
The current market value of these shares is $2,049,196. Vanguard Group INC boosted its holdings in Teleflex by 2.1% during the third quarter of this fiscal year.
After making an extra purchase of 110,456 shares during the period, Vanguard Group INC now has 5,339,526 shares of the medical technology company, worth $1,075,700,000.
Morgan Stanley’s ownership of Teleflex shares went up by 535.7 percent during the fourth fiscal quarter.
After purchasing an additional 2,267,889 shares during the period, Morgan Stanley now has 2,691,192 shares of the medical technology company, giving its holdings a value of $671,803,000.
Last but not least, during the third quarter, State Street Corporation raised its holdings in Teleflex by three percent. State Street Corp now owns 2,035,739 shares of the medical technology company’s stock, valued at $410,120,000, following the acquisition of an additional 58,500 shares during the period in question. Hedge funds and other institutional investors own 93.82% of the company’s stock.
Teleflex, INC develops medical technologies to aid medical professionals in enhancing patient outcomes while raising both patient and provider levels of safety.
The company designs, develops, manufactures, and sells one-time-use medical devices to hospitals and other healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.
These devices are intended for use in surgical and critical care settings.
Discussion about this post